At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
TAK-653 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-Controlled, 3-Period Crossover Study Followed by 1 Open-label Comparator Period to Evaluate Central Nervous System Pharmacodynamic Activity of TAK-653 in Healthy Volunteers Using Transcranial Magnetic Stimulation
In Brief
A Phase 1 clinical trial evaluating TAK-653, Placebo, and 1 other intervention for Healthy Volunteers. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The primary purpose of this study is to determine whether TAK-653, in comparison to placebo, increases CNS excitability, assessed with TMS-evoked motor-evoked potential (MEP) in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesNetherlands
CollaboratorsTakeda
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartFeb 2019
Primary CompletionMay 2019
Study CompletionJun 2019
TodayJul 2026
First PostedJan 3, 2019
Enrollment StartFeb 11, 2019
Primary CompletionMay 15, 2019
Study CompletionJun 18, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 7.5 years ago
Interventions
TAK-653drug
TAK-653 tablets.
Placebodrug
TAK-653 placebo-matching tablets.
Ketaminedrug
Ketamine intravenous infusion.